(LXRX) Lexicon Pharmaceuticals - Ratings and Ratios

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative pharmaceutical products. The companys pipeline focuses on orally-delivered small molecule drug candidates targeting significant unmet medical needs. Its lead candidate, Sotagliflozin, has completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes. This dual SGLT1/2 inhibitor aims to address both cardiac and metabolic benefits in patients with these conditions. Another key candidate, LX9211, is in Phase II clinical development for neuropathic pain, leveraging its unique mechanism of action to potentially offer improved efficacy over existing therapies. Additionally, LX2761 is in Phase I clinical development for gastrointestinal disorders, representing Lexicons expansion into new therapeutic areas. Lexicon has established strategic collaborations with major pharmaceutical companies, including Bristol-Myers Squibb and Genentech, to accelerate the development and commercialization of its pipeline. Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals operates with a focus on precision medicine and patient-centric drug development. Web URL: https://www.lexpharma.com

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a clinical-stage biopharmaceutical company with a market capitalization of $256.66M USD. The companys stock has shown recent price movements, with a last price of $0.70, below its 20-day SMA of $0.72 and 50-day SMA of $0.77, while significantly below its 200-day SMA of $1.40. The average trading volume over 20 days is 3,542,890 shares, with an ATR of 0.09, indicating moderate volatility. The companys forward P/E and current P/E are not available, reflecting its pre-profitability stage. The price-to-book ratio of 1.44 suggests the market values the company slightly above its book value, while the high price-to-sales ratio of 49.08 indicates expectations for future revenue growth.